HOUSE BILL 870

J1 (0lr1873)

ENROLLED BILL

— Health and Government Operations/Finance —

Introduced by Delegates Pena-Melnyk, Feldmark, Lehman, Proctor, and Valderrama, Bagnall, Barron, Hill, Johnson, Kerr, R. Lewis, Pendergrass, Rosenberg, and K. Young

Read and	Examined b	by Proofreaders:		
				Proofreader.
			·	Proofreader.
Sealed with the Great Seal and	presented	to the Governor	r, for his ap	oproval this
day of	at		o'clock,	M.
				Speaker.
	CHAPTER _			
AN ACT concerning				
Natalie M. LaPrade Medical Ca Use Fund , Standard Price I <u>(The</u>		ales at Reduced	_	
FOR the purpose of repealing red Commission, rather than the Compassionate Use Fund; preduring a certain period follogous preapproval of a license; repealing the Medical Cannabis Compassion of the Maryland Department of	e Maryland ohibiting the lowing the pealing a promission in date; repertain purpose	Department of Head of Experiment of Head of Experiment of a literature of a literature of the Experiment of the Experiment of Experiment of Experiment of Head of Head of Experiment of Head o	lealth, to add om imposing icense, rathe equiring the ain report to rity of the Co rovision of le	minister the certain fees er than the Natalie M. the General mmission to

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

<u>Underlining</u> indicates amendments to bill.

1

2 3 4

Strike out indicates matter stricken from the bill by amendment or deleted from the law by amendment.

Italics indicate opposite chamber/conference committee amendments.



1

2

3

4

5 6

7

8 9

10

11

12

13

14

15 16

24

than the Department, to establish a certain program to allow certain individuals to obtain medical cannabis at a reduced cost, rather than at no cost or a reduced cost, and reimburse a licensed dispensary for certain costs; requiring growers, processors, and dispensaries to maintain and make available a certain standard price list; prohibiting a grower, processor, and dispensary from selling medical cannabis or medical cannabis products at a price that exceeds the price indicated on the licensee's standard price list; requiring a licensed dispensary to offer for sale medical cannabis and medical cannabis products to a certain qualifying patient at a certain reduced cost; requiring a qualifying patient to present certain identification in order to purchase medical cannabis or medical cannabis products at a reduced cost; requiring dispensaries to submit a certain report to the Commission on or before a certain date each year; requiring the Commission to adopt regulations to implement this Act; making conforming changes stating the intent of the General Assembly; requiring the Commission to consider certain factors in developing certain regulations; making technical changes; and generally relating to the Natalie M. LaPrade Medical Cannabis Commission.

17 BY repealing and reenacting, with amendments,

18 Article – Health – General

19 Section 13–3303.1

20 Annotated Code of Maryland 21 (2019 Replacement Volume)

22 BY adding to

23 Article - Health - General

Section 13-3303.1

25 Annotated Code of Maryland 26 (2019 Replacement Volume)

27 BY repealing

28 Article - State Finance and Procurement

29 Section 6–226(a)(2)(ii)109. 30 Annotated Code of Maryland

31 (2015 Replacement Volume and 2019 Supplement)

32 BY renumbering

33 Article - State Finance and Procurement

34 Section 6-226(a)(2)(ii)110. through 122., respectively

35 to be Section 6-226(a)(2)(ii)109, through 121., respectively

36 Annotated Code of Maryland

37 (2015 Replacement Volume and 2019 Supplement)

38 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,

39 That the Laws of Maryland read as follows:

1	\f 13-3303.1.
---	----------------------

- 2 (a) In this section, "Compassionate Use Fund" means the Natalie M. LaPrade 3 Medical Cannabis Compassionate Use Fund.
- 4 (b) There is a Natalie M. LaPrade Medical Cannabis Compassionate Use Fund.
- 5 (c) (1) The Department COMMISSION shall:
- 6 (i) Administer the Compassionate Use Fund; and
- 7 (ii) Subject to paragraph (2) of this subsection, set fees in an amount 8 necessary to provide revenues for the purposes of the Compassionate Use Fund.
- 9 (2) The Commission may not impose the fees established under paragraph (1)(ii) of this subsection on a licensed medical cannabis grower, processor, or dispensary during the 2 years immediately following the preapproval ISSUANCE of the licensee for a license under this subtitle.
- 13 (d) The purpose of the Compassionate Use Fund is to provide access to medical cannabis for individuals enrolled in the Maryland Medical Assistance Program or in the Veterans Administration AFFAIRS Maryland Health Care System.
- 16 (e) (1) The Compassionate Use Fund is a special, nonlapsing fund that is not subject to § 7–302 of the State Finance and Procurement Article.
- 18 (2) The State Treasurer shall hold the Compassionate Use Fund 19 separately, and the Comptroller shall account for the Compassionate Use Fund.
- 20 (3) The Compassionate Use Fund shall be invested and reinvested in the same manner as other State funds, and any investment earnings shall be retained to the credit of the Compassionate Use Fund.
- 23 (4) The Compassionate Use Fund shall be subject to an audit by the Office 24 of Legislative Audits as provided for in § 2–1220 of the State Government Article.
- 25 (5) The Comptroller shall pay out money from the Compassionate Use 26 Fund as directed by the Department **COMMISSION**.
- 27 (f) (1) On or before December 1, 2018, the Commission, in consultation with 28 the Department, shall report to the General Assembly, in accordance with § 2–1257 of the 29 State Government Article, on:
- 30 (i) The revenues the Commission anticipates are necessary to 31 implement the program described in subsection (i) of this section;

${1 \atop 2}$	(ii) The amount of fees and the licensees on which those fees shall be assessed in order to generate the necessary revenues;
3 4	(iii) The use of any other funding mechanism to implement the program; and
5 6 7	(iv) Any anticipated savings in prescription drug costs for the Maryland Medical Assistance Program that would result from the provision of medical cannabis under this subtitle.
8 9 10	(2) The Commission may hire an independent actuary to assist the Commission in the preparation of the report required under paragraph (1) of this subsection.
11	(g) (F) No part of the Compassionate Use Fund may revert or be credited to:
12	(1) The General Fund of the State; or
13	(2) Any other special fund of the State.
14 15	(h) (G) Expenditures from the Compassionate Use Fund may be made only in accordance with the State budget.
16 17 18 19	(i) (H) (1) The Department, in consultation with the Commission, shall establish a program to allow eligible individuals enrolled in the Maryland Medical Assistance Program or in the Veterans Administration AFFAIRS Maryland Health Care System to:
20 21	(i) Obtain medical cannabis from a licensed dispensary at no cost or a reduced cost; and
22 23 24	(ii) Reimburse a licensed dispensary for the cost of the medical cannabis dispensed to an eligible individual under the program from the Compassionate Use Fund.
25 26	(2) The $\frac{\text{Commission}}{\text{Department}}$ shall adopt regulations to implement this subsection.
27	13-3303.1.
28 29 30	(A) EACH GROWER, PROCESSOR, AND DISPENSARY SHALL MAINTAIN AND MAKE AVAILABLE A STANDARD PRICE LIST THAT INCLUDES ANY MEDICAL CANNABIS AND MEDICAL CANNABIS PRODUCT OFFERED FOR SALE BY THE LICENSEE.

1 2	(B) A GROWER, PROCESSOR, OR DISPENSARY MAY NOT SELL MEDICAL CANNABIS OR A MEDICAL CANNABIS PRODUCT AT A PRICE THAT EXCEEDS THE PRICE
3	INDICATED ON THE LICENSEE'S STANDARD PRICE LIST.
4	(C) A DISPENSARY SHALL OFFER FOR SALE MEDICAL CANNABIS AND
5	MEDICAL CANNABIS PRODUCTS TO A QUALIFYING PATIENT ENROLLED IN THE
6	MARYLAND MEDICAL ASSISTANCE PROGRAM OR IN THE VETERANS
7	Administration Maryland Health Care System at a reduced cost of not
8	LESS THAN 20% OF THE PRICE INDICATED ON THE DISPENSARY'S STANDARD PRICE
9	LIST.
0	(D) A QUALIFYING PATIENT MUST PRESENT THE FOLLOWING TO A
1	DISPENSARY AT THE TIME OF PURCHASE IN ORDER TO PURCHASE MEDICAL
2	CANNABIS OR A MEDICAL CANNABIS PRODUCT AT A REDUCED COST:
13	(1) A VALID:
4	(I) MARYLAND MEDICAL ASSISTANCE CARD; OR
15	(II) VETERAN HEALTH IDENTIFICATION CARD (VHIC); AND
	(a) A Construction region of the first property of the first prope
16	(2) A COMMISSION ISSUED QUALIFYING PATIENT IDENTIFICATION
L 7	CARD.
18	(E) ON OR BEFORE JULY 30 EACH YEAR, EACH DISPENSARY SHALL SUBMIT
9	A REPORT TO THE COMMISSION, IN A FORM PRESCRIBED BY THE COMMISSION, THAT
20	INCLUDES:
21	(1) THE AMOUNT OF REDUCED-COST SALES MADE BY THE
22	DISPENSARY; AND
23	(2) A LIST OF ELIGIBLE QUALIFYING PATIENTS WHO RECEIVED
24	REDUCED COST MEDICAL CANNABIS OR MEDICAL CANNABIS PRODUCTS.
25	(F) THE DEPARTMENT SHALL ADOPT REGULATIONS TO IMPLEMENT THIS
26	SECTION.
27	Article - State Finance and Procurement
4 (Mither State Phiance and Procurement
28	6-226.
29	(a) (2) (ii) The provisions of subparagraph (i) of this paragraph do not apply
30	to the following funds:

33

34

1109. the Natalie M. LaPrade Medical Cannabis Compassionate 1 2Use Fund; 3 SECTION 2. AND BE IT FURTHER ENACTED, That Section(s) 6-226(a)(2)(ii)110. through 122., respectively, of Article - State Finance and Procurement of the Annotated 4 Code of Maryland be renumbered to be Section(s) 6-226(a)(2)(ii)109. through 121., 5 6 respectively: 7 (a) It is the intent of the General Assembly that the Natalie M. LaPrade Medical 8 Cannabis Commission, to support the Compassionate Use Fund and the program established under § 13–3301.1(h) of the Health – General Article, as enacted by Section 1 9 of this Act: 10 11 establish a fee structure that, in addition to meeting the requirements (1)of § 13–3303.1 of the Health – General Article, as enacted by Section 1 of this Act, assesses 12 fees on licensed medical cannabis growers, processors, and dispensaries; 13 in establishing a fee structure, consider the financial and 14 (2)administrative burden placed on medical cannabis licensees in the initial stages of 15 16 establishing the program under § 13–3301.1(h) of the Health – General Article, as enacted 17 by Section 1 of this Act: 18 (3) establish procedures for assessing and collecting fees under § 13–3301.1 of the Health – General Article, as enacted by Section 1 of this Act; and 19 20 provide reimbursement to licensed medical cannabis dispensaries 21under the program established under § 13–3301.1(h) of the Health – General Article, as 22 enacted by Section 1 of this Act, in a manner that minimizes the financial and administrative burden on the Commission and the licensed medical cannabis growers, 2324processors, and dispensaries. 25(b) In developing the regulations to implement the Compassionate Use Fund and 26 program established under § 13–3301.1(h) of the Health – General Article, as enacted by 27 Section 1 of this Act, the Commission shall consider: 28measures that may be implemented to identify and deter diversion of (1) medical cannabis and medical cannabis products; 2930 methods for assisting licensed medical cannabis dispensaries in determining the eligibility of patients; and 31 32 whether § 280(e) of the Internal Revenue Code impacts any fee (3)

SECTION 3. AND BE IT FURTHER ENACTED, That this Act shall take effect October 1, 2020.

13–3301.1(h) of the Health – General Article, as enacted by Section 1 of this Act.

structure used to support or the administration of the program established under §

oproved:	
	Governor
	Speaker of the House of Delegates
	President of the Senate